D-0726-2021 Class II Terminated

Recalled by Novel Laboratories, Inc. D.B.A LUPIN — Somerset, NJ

FDA drug recall D-0726-2021 was initiated by Novel Laboratories, Inc. D.B.A LUPIN on Jul 29, 2021 and is designated Class II. Reason for recall: Failed Stability Specification; Out of specification for Osmolarity The recall status is terminated (terminated Nov 14, 2022). Affected quantity: 20,814 bottles.

Recall details

Product Type
Drugs
Report Date
Aug 25, 2021
Initiation Date
Jul 29, 2021
Termination Date
Nov 14, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
20,814 bottles

Product description

GaviLyteTM - C PEG-3350 (240g) and Electrolytes for Oral Solution, USP with Flavor Pack Manufactured by Novel Laboratories, Inc. Somerset, NJ 08873, USA Manufactured for Lupin Pharmaceuticals, Inc. Baltimore, MD 21202 NDC 43386-060-19

Reason for recall

Failed Stability Specification; Out of specification for Osmolarity

Distribution pattern

Nationwide

Code information

Lot S001133, exp 7/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0726-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0726-2021. Report a data issue: hello@regdatalab.com.